Genenta Science SpA ADR (GNTA)

Name: Genenta Science SpA ADR (GNTA) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Genenta Science SpA ADR (GNTA)

Stock Card

$1.03

$0.01 (0.98%)

As on 01-Sep-2026 10:55EDT

Market cap

$48 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

1.9

Div. Yield

0 %

Genenta Science SpA ADR (GNTA) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.98 High: 1.04

52 Week Range

Low: 0.55 High: 10.00

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-7 Mln
ROE

-0.4 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-11.5
Debt to Equity

0.3
Book Value

$1.2
EPS

$-0.3
Face value

--
Shares outstanding

48,216,858

5 Years Aggregate

CFO

€-33.89 Mln

EBITDA

€-40.46 Mln

Net Profit

€-30.81 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Genenta Science SpA ADR (GNTA)	-30.9	-30.9	0.0	-72.6	-43.8	--	--
BSE Sensex	-9.1	-1.5	2.9	-3.6	5.9	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023
Genenta Science SpA ADR (GNTA)	-65.7	-12.0	-10.0
S&P Small-Cap 600	4.0	7.0	13.9
BSE Sensex	9.1	8.1	18.7

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Genenta Science SpA ADR (GNTA)	1.0	48.2	0.0	-6.3	--	-36.5	--	1.9
Ascendis Pharma A/S - ADR	262.1	16,261.1	1,054.4	755.9	5.7	--	19	9.8

Shareholding Pattern

View Details

About Genenta Science SpA ADR (GNTA)

Genenta Science S.p.A., a clinical-stage biotechnology company, develops hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company offers Temferon, which is in Phase 1/2a clinical trials for use in the treatment... of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is developing Temferon for use in the treatment of other solid tumor indications. In addition, the company develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy. Read more

Vice Chairman of the Board, CEO & GM

Mr. Pierluigi Paracchi
Vice Chairman of the Board, CEO & GM

Mr. Pierluigi Paracchi
Headquarters

Milan, MI
Website

https://www.genenta.com

FAQs for Genenta Science SpA ADR (GNTA)

What is the current share price of Genenta Science SpA ADR (GNTA) Today?

The share price of Genenta Science SpA ADR (GNTA) is $1.03 (NASDAQ) as of 01-Sep-2026 10:55 EDT. Genenta Science SpA ADR (GNTA) has given a return of -43.79% in the last 3 years.

What is the current PB & PE ratio of Genenta Science SpA ADR (GNTA)?

Since, TTM earnings of Genenta Science SpA ADR (GNTA) is negative, P/E ratio is not available.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-4.46	1.28
2024	-8.55	6.37
2023	-7.88	4.41
2022	-12.10	3.22
2021	-34.64	5.14

What is the 52 Week High and Low of Genenta Science SpA ADR (GNTA)?

The 52-week high and low of Genenta Science SpA ADR (GNTA) are Rs 10.00 and Rs 0.55 as of 01-Sep-2026.

What is the market cap of Genenta Science SpA ADR (GNTA)?

Genenta Science SpA ADR (GNTA) has a market capitalisation of $ 48 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Genenta Science SpA ADR (GNTA)?

Before investing in Genenta Science SpA ADR (GNTA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.